Trial Profile
A single ascending dose(SAD) and single ascending dose (MAD ) phase I trial of TP-6076 in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2018
Price :
$35
*
At a glance
- Drugs TP 6076 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 05 Oct 2018 Results of the multiple ascending dose study presented at the IDWeek 2018.
- 19 Sep 2018 According to Tetraphase Pharmaceuticals media release, data from this trial will be presented at the Infectious Disease Society of Americas (IDSA) Infectious Disease Week (IDWeek) 2018.
- 02 Aug 2018 According to a Tetraphase Pharmaceuticals media release, the company anticipates completing MAD potion in 2H 2018.